Wolfgang E. Berdel

1980–2025 年に発表

183
論文数
28,845
被引用数
99
h 指数
181
i10 指数

被引用数

Wolfgang E. Berdel の年別被引用数1943 年: 被引用 1 件1979 年: 被引用 3 件1987 年: 被引用 3 件1988 年: 被引用 1 件1990 年: 被引用 2 件1991 年: 被引用 6 件1992 年: 被引用 5 件1994 年: 被引用 3 件1995 年: 被引用 7 件1996 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 6 件1999 年: 被引用 2 件2000 年: 被引用 6 件2001 年: 被引用 50 件2002 年: 被引用 85 件2003 年: 被引用 120 件2004 年: 被引用 161 件2005 年: 被引用 177 件2006 年: 被引用 171 件2007 年: 被引用 190 件2008 年: 被引用 162 件2009 年: 被引用 205 件2010 年: 被引用 193 件2011 年: 被引用 213 件2012 年: 被引用 229 件2013 年: 被引用 248 件2014 年: 被引用 287 件2015 年: 被引用 245 件2016 年: 被引用 293 件2017 年: 被引用 324 件2018 年: 被引用 270 件2019 年: 被引用 1,037 件2020 年: 被引用 1,006 件2021 年: 被引用 945 件2022 年: 被引用 678 件2023 年: 被引用 509 件2024 年: 被引用 769 件2025 年: 被引用 305 件2026 年: 被引用 3 件1944〜1978 年は被引用が無いため表示していません1980〜1986 年は被引用が無いため表示していません1989 年は被引用が無いため表示していません1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,966 件、この内訳の 24.2%中国: 引用元論文 1,627 件、この内訳の 13.3%ドイツ: 引用元論文 1,212 件、この内訳の 9.9%イギリス: 引用元論文 658 件、この内訳の 5.4%イタリア: 引用元論文 617 件、この内訳の 5%フランス: 引用元論文 509 件、この内訳の 4.2%オランダ: 引用元論文 380 件、この内訳の 3.1%カナダ: 引用元論文 366 件、この内訳の 3%日本: 引用元論文 332 件、この内訳の 2.7%スペイン: 引用元論文 284 件、この内訳の 2.3%スイス: 引用元論文 268 件、この内訳の 2.2%オーストラリア: 引用元論文 266 件、この内訳の 2.2%
0%24.2%その他 22.5%

分野

  • Medicine57.2%
  • Biochemistry, Genetics and Molecular Biology34.7%
  • Immunology and Microbiology2.7%
  • Materials Science1.2%
  • Engineering1.1%
  • Neuroscience1%
  • その他2.1%

トピック

  • Acute Myeloid Leukemia Research10.7%
  • Cancer-related molecular mechanisms research5.2%
  • RNA modifications and cancer4%
  • Chronic Myeloid Leukemia Treatments3.3%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment2.6%
  • RNA Research and Splicing2.4%
  • その他71.8%

共著者

全論文

検索で開く
  1. A 17-gene stemness score for rapid determination of risk in acute leukaemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2016 被引用: 939

  2. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer

    著者: , , , , , , , , , , , , , - Oncogene 2003 被引用: 2,190

  3. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 被引用: 164

  4. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hiroko Tanaka, Satoru Miyano, Kenichi Yoshida, Seishi Ogawa, Carsten Müller‐Tidow, Jaroslaw P. Maciejewski - Cancer Cell 2015 被引用: 435

  5. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 被引用: 339

  6. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 77

  7. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , - Leukemia 2023 被引用: 98

  8. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 被引用: 534

  9. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heinz Dürk, Jana Hase, Ina‐Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Krämer, Wolfgang E. Berdel, Gerhard Ehninger - The Lancet Oncology 2015 被引用: 400

  10. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 被引用: 267

  11. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cell Biology 2017 被引用: 192

  12. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2021 被引用: 76

  13. Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Georg Maschmeyer, Ingo Brink, Helga Bernhard, Uwe Haberkorn, Tobias Gaska, Lars Kurch, Daniëlle M. E. van Assema, Wolfgang Hiddemann, Dieter Hoelzer, Lilli Geworski, Karl‐Heinz Jöckel, André Scherag, Andreas Bockisch, Jan Rekowski, Andreas Hüttmann, on behalf of the PETAL Trial Investigators - Journal of Clinical Oncology 2018 被引用: 251

  14. Multiparametric MRI for characterization of the tumour microenvironment

    著者: , , , , , , , , , - Nature Reviews Clinical Oncology 2024 被引用: 75

  15. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2008 被引用: 445

  16. The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth

    著者: , , , , , , , , , , , , , - Journal of Thoracic Oncology 2011 被引用: 547

  17. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2017 被引用: 140

  18. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Friedrich Stölzel, Malte von Bonin, Jan Moritz Middeke, Christian Thiede, Johannes Schetelig, Wolfgang E. Berdel, Gerhard Ehninger, Claudia D. Baldus, Carsten Müller‐Tidow, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser - Blood 2020 被引用: 135

  19. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elihu H. Estey, Carole Shaw, Rita Exeler, Lisa Wagenführ, Friedrich Stölzel, Christian Thiede, Matthias Stelljes, Georg Lenz, Jan-Henrik Mikesch, Hubert Serve, Gerhard Ehninger, Wolfgang E. Berdel, Michael Krämer, Utz Krug, Christoph Schliemann - Journal of Clinical Oncology 2019 被引用: 116

  20. The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches

    著者: , , , , , , - Nature Reviews Clinical Oncology 2019 被引用: 131

  21. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hubert Serve, Gerhard Ehninger, Alexander H. Schmidt, Martin Bornhäuser, Jan‐Henrik Mikesch, Johannes Schetelig, Nael Alakel, Jörn C. Albring, Wolfgang E. Berdel, Wolfgang Bethge, Martin Bornhäuser, Gesine Bug, Christoph Buhl, Simon Call, Martina Crysandt, Katharina Egger‐Heidrich, Eva Eßeling, Christoph Faul, Georg‐Nikolaus Franke, Julia-Annabell Georgi, Julia Glück-Wolf, Christoph Groth, Beate Hauptrock, Daniela Heidenreich, Snjezana Janjetovic, Edgar Jost, Martin Kaufmann, Thomas Kindler, Stefan Klein, Stefan W. Krause, Sebastian Kreil, Theresa Kretschmann, Desireé Kunadt, Fabian Lang, Georg Lenz, Sonja Martin, Julia Marx, Jan-Moritz Middeke, Jan‐Henrik Mikesch, Lutz Müller, Nadine Müller, Judith Niederland, Stefani Parmentier, Kathrin Petzold, Uwe Platzbecker, Andreas Rank, Christian Reicherts, Christoph Röllig, Wolf Rösler, Kerstin Schäfer‐Eckart, Judith Schaffrath, Markus Schaich, Johannes Schetelig, Christoph Schliemann, Christoph Schmid, Dominik Schneidawind, Jörg Schubert, Hubert Serve, Katja Sockel, Björn Steffen, Matthias Stelljes, Raphael Teipel, Malte von Bonin, Eva Wagner-Drouet, Maxi Wass, Knut Wendelin - The Lancet Haematology 2024 被引用: 49

  22. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Johannes Schetelig, Jan Moritz Middeke, Hubert Serve, Claudia D. Baldus, Uwe Platzbecker, Carsten Müller‐Tidow, Martin Bornhäuser, Tobias Herold, Christian Thiede, Christoph Röllig - Leukemia 2023 被引用: 36

  23. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2005 被引用: 648

  24. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 被引用: 272